Venous Thromboembolism and Bleeding with Temozolomide-, Bevacizumab-, and Nitrosourea-Based Therapy in Glioma: A Dual-Database Pharmacovigilance Study.

ABSTRACT: Introduction: Patients with malignant glioma are inherently at high risk of venous thromboembolism (VTE) and bleeding, and systemic therapy may further modify this vascular risk. This study used large spontaneous reporting databases to compare VTE, central nervous system (CNS) bleeding and gastrointestinal (GI) bleeding signals associated with four representative systemic therapies for glioma-temozolomide, bevacizumab and the nitrosourea alkylating agents lomustine and carmustine-and explore bevacizumab-based combination regimens. Methods: We conducted a retrospective pharmacovigilance study using the FAERS and the CVARD, identifying reports of patients with gliomas exposed to temozolomide, bevacizumab, lomustine or carmustine. VTE, CNS bleeding and GI bleeding were defined a

SUBMITTER: Hou X 

PROVIDER: S-EPMC12784670 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature